TransMedics Group, Inc. $TMDX Stock Position Raised by Peregrine Capital Management LLC

Peregrine Capital Management LLC lifted its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 16.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 68,406 shares of the company’s stock after purchasing an additional 9,676 shares during the period. Peregrine Capital Management LLC owned approximately 0.20% of TransMedics Group worth $7,675,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock worth $209,448,000 after purchasing an additional 2,209,996 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of TransMedics Group by 258.7% in the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after buying an additional 394,340 shares during the period. Zevenbergen Capital Investments LLC increased its position in shares of TransMedics Group by 112.7% in the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock worth $29,006,000 after acquiring an additional 136,995 shares in the last quarter. Next Century Growth Investors LLC purchased a new position in shares of TransMedics Group in the second quarter worth approximately $16,049,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after acquiring an additional 86,721 shares during the period. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Trading Down 0.4%

TransMedics Group stock opened at $137.07 on Friday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $156.00. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The stock has a market cap of $4.68 billion, a P/E ratio of 55.49 and a beta of 2.03. The company’s fifty day simple moving average is $129.05 and its 200-day simple moving average is $122.29.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. During the same quarter last year, the firm earned $0.12 earnings per share. The business’s revenue for the quarter was up 32.2% on a year-over-year basis. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TMDX. Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Evercore ISI initiated coverage on TransMedics Group in a report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 target price for the company. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a report on Sunday, December 28th. Needham & Company LLC upped their price target on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Finally, Jefferies Financial Group assumed coverage on TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price objective for the company. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.25.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 4,142 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the transaction, the director owned 2,866 shares in the company, valued at approximately $373,869.70. This represents a 59.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Anil P. Ranganath sold 3,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares of the company’s stock, valued at $2,026,545.10. This trade represents a 17.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 13,062 shares of company stock worth $1,797,634. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.